Type 2 diabetes
Conditions
Interventions
DPP4 (Alogliptin) treatment group
Clinical investigators will initiate alogliptin treatment in addition to the existing single medication. Treatment will be continued to achieve the target value specified in the diabetes treatment gui
Clinical investigators will initiate alpha-glucosidase inhibitor (Acarbose) treatment in addition to the existing single medication. Treatment will be continued to achieve the target value specified i
Sponsors
Tokyo Women's Medical University
Institute of Geriatrics Tokyo Women'
s Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. twenty years of age or older (regardless of gender) 2.Type 2 diabetes patients (HbA1c (NGSP value) higher then 6.2% and below 8.4%) in whom the target of blood glucose control specified in the 2010 diabetes treatment guidelines is not achieved despite the single therapeutic drugs for diabetes other than a DPP-4 inhibitor being performed for 3 months or longer 3.Written consent for participation in the study
Exclusion criteria
Exclusion criteria: Patients meeting one of the following conditions will be excluded: 1.Under treatment with a thiazolinean, dual or more diabetis drugs, other DPP-4 inhibitors or insulin at the time of study initiation 2. Type 2 and secondary diabetes 3. Severe infectious disease, before or after surgery, and severe trauma 4. Events of myocardial infarction, angina pectoris, cerebral stroke, and cerebral infarction 5. Moderate renal dysfunction (Serum creatinine (mg/dL): male, 1.4<; female, 1.2<) 6. Severe liver dysfunction (AST: 100 IU/l or higher) 7. Moderate or severer heart failure) (NYHA/New York Heart Association stage III or severer) 8. Under insulin treatment 9. Under treatment with therapeutic drugs not concomitantly administrable with incretin preparations, such as DPP-4 inhibitors, with regard to national health insurance, at the time of study initiation 10. Pregnant, lactating, and possibly pregnant women and those planning to become pregnant 11. Past medical history of hypersensitivity to investigational drugs 12) Judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in the serum micro-RNA during a 6-month treatment period | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes of following data 1.FBS, HbA1c 2.urinary micro albmin 3.BUN, Cr, Cystatine C 4.the grade of diebetis retinopaty | — |
Countries
Japan
Contacts
Public ContactHARUKI SEKIGUCHI
Aoyama Hospital, Tokyo Women's Medical University Cardiology
Outcome results
None listed